We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity

This study has been terminated.
(Limitation of funding)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00303082
First Posted: March 15, 2006
Last Update Posted: June 15, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ministry of Health, Brazil
Information provided by:
Oswaldo Cruz Foundation
  Purpose
The trial intends to evaluate the efficacy of specially designed probiotics to prevent premature birth and related neonatal morbidity associated to intra-uterine infection. The tested probiotics are efficacious to decrease the prevalence of bacterial vaginosis. The study hypothesis is that the early administration of those probiotics to pregnant women with bacterial vaginosis can prevent premature birth through antibiotic activity and modulation of the immune response to infection.

Condition Intervention Phase
Bacterial Vaginosis Premature Birth Sepsis Periventricular Leukomalacia Bronchopulmonary Dysplasia Drug: Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Clinical Trial for the Prevention of Premature Birth and Neonatal Related Morbidity

Resource links provided by NLM:


Further study details as provided by Oswaldo Cruz Foundation:

Primary Outcome Measures:
  • Spontaneous premature birth (<37, <35, <32 weeks of pregnancy) [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • and related neonatal events: early sepsis, bronchopulmonary dysplasia, cystic periventricular leukomalacia, ventricular hemorrhage and retinopathy, besides neonatal death. [ Time Frame: 28 weeks ]
  • Variation in Nugent Score (before/after intervention) [ Time Frame: 9 weeks ]
  • Variation in selected cytokine levels(before/after intervention) [ Time Frame: 9 weeks ]

Enrollment: 645
Study Start Date: January 2006
Study Completion Date: August 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-Asymptomatic pregnant women with no indication of elective preterm delivery, before the 20th week of pregnancy

Exclusion Criteria:

  • major malformations in present pregnancy
  • cervical cerclage
  • symptomatic vaginosis
  • insulin dependent diabetes
  • arterial hypertension
  • Multiple gestation
  • Antibiotic therapy in present pregnancy
  • Syphilis or gonorrhea in present pregnancy
  • asthma requiring chronic or intermittent therapy
  • corticotherapy(recent or chronic)
  • perinatal hemolytic disease
  • Systemic Erit. Lupus
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00303082


Locations
Brazil
Hospital Maternidade Alexander Fleming
Rio de Janeiro, Brazil
Hospital Maternidade Carmela Dutra
Rio de Janeiro, Brazil
Sponsors and Collaborators
Oswaldo Cruz Foundation
Ministry of Health, Brazil
Investigators
Principal Investigator: Leticia Krauss-Silva, MD, Ph.D Oswaldo Cruz Foundation
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Leticia Krauss Silva, Oswaldo Cruz Foundation
ClinicalTrials.gov Identifier: NCT00303082     History of Changes
Other Study ID Numbers: MDTP2/PDTSP-SUS
First Submitted: March 13, 2006
First Posted: March 15, 2006
Last Update Posted: June 15, 2011
Last Verified: October 2009

Keywords provided by Oswaldo Cruz Foundation:
Probiotics
Bacterial Vaginosis
Premature birth
Intra-uterine Infection
Periventricular leukomalacia

Additional relevant MeSH terms:
Leukomalacia, Periventricular
Premature Birth
Vaginal Diseases
Bronchopulmonary Dysplasia
Vaginosis, Bacterial
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Genital Diseases, Female
Ventilator-Induced Lung Injury
Lung Injury
Lung Diseases
Respiratory Tract Diseases
Infant, Premature, Diseases
Infant, Newborn, Diseases
Bacterial Infections
Vaginitis
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Encephalomalacia
Vascular Diseases
Cardiovascular Diseases